Name in SEC filings: Rapport Therapeutics, Inc.
Source: ORION, orionbiotechai.com/company/RAPP, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/RAPP
RAP-219 · Topline/data readout · October 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
bipolar mania
Topline/data readoutOctober 2026
Stage: Phase 2SEC filing · “Phase 2”
Public float: $275,840,930 · as of · SEC filing
topline results are expected in October 2026.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-10)
drug-resistant FOS
Topline/data readoutthe fourth quarter of 2026
Stage: Not stated
Public float: $275,840,930 · as of · SEC filing
Data from the open-label trial is expected in the fourth quarter of 2026.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2027
Stage: Phase 1SEC filing · “Phase 1”
Public float: $275,840,930 · as of · SEC filing
IND-enabling activities for RAP-219's long-acting injectable formulation continue, with initial Phase 1 pharmacokinetic data expected in 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| RAP-219Clinical results | the fourth quarter of 2026“Data from the open-label trial is expected in the fourth quarter of 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| RAP-219Clinical results | October 2026“topline results are expected in October 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| RAP-219 long-acting injectableClinical results | 2027“IND-enabling activities for RAP-219's long-acting injectable formulation continue, with initial Phase 1 pharmacokinetic data expected in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| RAP-219Clinical results | the second half of 2026“Data from the open-label trial is expected in the second half of 2026.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| RAP-219Clinical results | the second half of 2026“Data from the trial is expected to be released in the second half of 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| RAP-219Clinical results | the fourth quarter of 2026“topline results are now expected in the fourth quarter of 2026” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| RAP-219Clinical results | the fourth quarter of 2026“topline results are now expected in the fourth quarter of 2026” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| RAP-219Clinical results | the fourth quarter of 2026“RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| RAP-219 long-acting injectableClinical results | 2027“Development of RAP-219’s long-acting injectable formulation continues to advance, with IND-enabling activities underway and initial Phase 1 pharmacokinetic data expected in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| RAP-219Clinical results | the second half of 2026“initial data from the OLE are expected in the second half of 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| RAP-219 long-acting injectableClinical results | 2027“Additionally, Rapport continues development of a long-acting injectable (LAI) formulation of RAP-219, with Phase 1 initial PK results expected in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
These dated records retain their original scope and check dates.
Record RAPP-BM-P2 · Clinical results disclosure · Timing changed
Last checked: .
· Checked by founder · SEC 8-K, Exhibit 99.1
Stated period: in the first half of 2027
topline results expected in the first half of 2027
· Checked by founder · SEC 8-K, Exhibit 99.1
Stated period: in the fourth quarter of 2026
topline results are now expected in the fourth quarter of 2026
· Checked by founder · SEC 8-K, Exhibit 99.1
Stated period: in October 2026
topline results expected in October 2026
· Checked by founder · SEC Form 10-Q
Stated period: in October 2026
topline results are expected in October 2026
· Checked by founder · SEC 8-K, Exhibit 99.1
Enrollment in the Phase 2 trial is progressing well and topline results are now expected in the fourth quarter of 2026, ahead of the previous guidance of first half of 2027.
Exhibit 99.1: Bipolar Mania Phase 2 Trial Topline Results section; sentence beginning Enrollment in the Phase 2 trial
Company release: · Company original
Company release: · Company original
Company release: · Company original
March 11, 2025 is the earliest date in these four founder-reviewed sources. Earlier RAPP statements in the wider research inventory have not been imported as founder-reviewed records.
The two August 5, 2026 documents are shown separately. Each is compared with the preceding checked date, not with the other document from August 5.
The 2025-03-11 source labels the trial Phase 2a; the later selected sources use Phase 2. The founder confirmed the common bipolar-mania topline event in these four sources.
SEC filings searched through : The founder compared four selected SEC sources on 2026-10-12: the 2025-03-11, 2026-05-07 and 2026-08-05 Exhibit 99.1 statements and the 2026-08-05 Form statement. RAPP's SEC filing list was checked through 2026-10-12: after 2026-08-05 it lists Forms 4, 144 and SC 13G/A and no other filings; none of these reports trial results.
Company press releases checked : The company press-release statements checked are the ones preserved as SEC Exhibit 99.1 in the four reviewed sources. The issuer website archive was not checked.
Checked by founder: .
Rapport Therapeutics (RAPP) — RAP-219 / bipolar mania Phase 2 · Topline results: “in the first half of 2027” (SEC 8-K, Exhibit 99.1 2025-03-11); wording changed from “in the first half of 2027” (2025-03-11) to “in the fourth quarter of 2026” (2026-05-07); wording changed from “in the fourth quarter of 2026” (2026-05-07) to “in October 2026” (2026-08-05); wording changed from “in the fourth quarter of 2026” (2026-05-07) to “in October 2026” (2026-08-05). Status Timing changed, checked 2026-10-12. Sources: https://www.sec.gov/Archives/edgar/data/2012593/000095017025036822/rapp-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/2012593/000119312526210324/rapp-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/2012593/000119312526333862/rapp-20260630.htm
topline results are expected in October 2026
Suggest an SEC timing statement to add for RAPP. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See RAPP in the calendar · Review labels and methodology